Brand Intelligence Graph
Company Overview
About Superluminal Medicines
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
Business Model & Competitive Advantage
Superluminal's AI GPCR drug discovery platform addresses the conformational complexity that makes most GPCRs undruggable by conventional methods: GPCRs are membrane proteins that exist in multiple conformational states — their three-dimensional structure changes dynamically based on which signaling pathways are active, making it difficult to design small molecules that selectively bind one conformation (the therapeutically relevant one) without hitting off-target conformations that cause side effects. Superluminal's combination of AI-predicted protein dynamics (modeling GPCR conformational states across time), structural biology validation (cryo-EM and crystallography data to confirm binding modes), and generative chemistry (designing molecules that exploit the predicted binding pockets) enables rational drug design for GPCR targets that structure-based drug design methods fail on because the relevant binding conformation doesn't crystallize easily.
Competitive Landscape 2025–2026
In 2025, Superluminal competes in the AI drug discovery, GPCR therapeutics, and cardiometabolic drug development market with Schrödinger (NASDAQ: SDGR, computational drug design platform, $200M revenue), Recursion (NASDAQ: RXRX, AI drug discovery at scale, $400M+ raised), and Relay Therapeutics (NASDAQ: RLAY, protein dynamics drug design, $700M raised) for pharmaceutical partner AI-driven small molecule drug discovery and GPCR target development collaboration. Eli Lilly's $1.3B collaboration (in August 2025) validates Superluminal's platform at the highest tier of pharmaceutical partnership investment. NVIDIA NVentures' participation reflects AI computational infrastructure investment in the drug discovery application. RA Capital's Series A leadership provides deep biotech public market expertise. The 2025 strategy focuses on advancing the MC4R obesity program to IND filing, building the GPCR discovery pipeline for additional cardiometabolic targets under the Lilly collaboration, and expanding the platform to Class B/C GPCRs in neurological and inflammatory disease areas.
The Superluminal Medicines Story
Founders
Company Timeline
Major milestones in Superluminal Medicines's journey
Leadership Team
Meet the leaders behind Superluminal Medicines
Cony D'Cruz
Co-founded Superluminal in 2022 and leads the company as CEO. Oversees strategic direction, partnerships, and overall operations.
Ajay Yekkirala
Former postdoc at Harvard Medical School and Boston Children's Hospital. Previously co-founded Blue Therapeutics and served as VP and Head of Biology at RA Capital Management.
Yang-Ming Zhu
Leads engineering and technology development for Superluminal's AI-driven drug discovery platform.
Yamina A. Berchiche
Leads biological research programs and contributes to target validation and drug candidate development.
Marek Orzechowski
Leads computational chemistry efforts supporting AI-driven drug design and optimization.
Murco Ringnalda
Oversees operations and strategic execution across the organization.
Key Differentiators
Market Leader
Superluminal Medicines is recognized as a market leader in the Healthcare sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Superluminal Medicines with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Superluminal Medicines? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Superluminal Medicines Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Superluminal Medicines vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →